Coronary Thrombolysis

Tirofiban-induced coronary thrombolysis.

receptor antagonists during coronary angioplasty has become more widespread due to several trials demonstrating clinical benefit during and after the p r o c e d u r e . – 3 These agents act by blocking the GP IIb/IIIa receptor on the surface of the platelet. The GP IIb/IIIa receptor binds circulating adhesive macromolecules and cross-links with the receptors of surrounding platelets, resulting...

Current concepts in coronary thrombolysis.

Thrombolytic therapy has become standard care in treating acute myocardial infarction. Fibrinolytic drugs such as streptokinase, APSAC and urokinase are non fibrin specific, and induce systemic activation of the fibrinolytic process, while t-PA and prourokinase are fibrin specific since they are able to activate mainly fibrin bound plasminogen. Both groups of thrombolytics exert different and o...

Successful and unsuccessful coronary thrombolysis.

LABORATORY INVESTIGATION CORONARY THROMBOLYSIS Coronary thrombolysis in dogs with intravenously administered human pro-urokinase

Coronary thrombolysis was induced by infusion of highly purified human pro-urokinase isolated from a transformed kidney cell line (ACHN) or by infusion of urokinase of urinary origin in anesthetized dogs with 1-hr-old clots in the left anterior descending coronary artery. The clots were induced with a copper coil and thrombolysis was detected by repeat coronary angiography. Intravenous infusion...

Role of heparin in coronary thrombolysis.

Although the benefits of coronary thrombolysis are well established, the optimal therapeutic strategy for ensuring rapid and sustained coronary artery patency remains controversial. The available data suggest that the success of coronary thrombolysis depends not only on the induction of clot lysis, but also on the extent to which procoagulant activity that promotes recurrent thrombosis is inhib...